Stephanie Graff shared a post on X:

“Getting excited for ASCO24 Annual Meeting.
Abstract titles are officially out.

And no surprise, for breast cancer the reign of Antibody-Drug Conjugates (ADC) continues. At first glance, some anticipated results for Dato-DXd and T-DXd from Rebecca Shatsky, Fabrice Andre, and Sonia Pernas.

Also, at ASCO24 the long awaited postmonarch trial (to extend or not to extend—that is the question) and more detail on how we may incorporate ctDNA into personalized care by Kevin Kalinsky, Sherene Loi.

And of course I’m so proud of Don Dizon from Legorreta Cancer Center at Brown University, The Brown University Oncology Research Group (BrUOG) for this Rhode Island -grown gynecological cancer trial hitting the podium!

What a great program! Congrats to ASCO President Lynn M. Schuchter and Scientific Chair Angie DeMichele.
See you in Chicago!

”

Source: Stephanie Graff/X

Stephanie L. Graff is the Director of the Breast Oncology Program at Lifespan Cancer Institute at the Legorreta Cancer Center at Brown University and co-leader of the Breast Cancer Translational Research Disease Group. She is an Associate Professor of Medicine at the Warren-Alpert School of Medicine. She also serves as a medical advisor to the Dr. Susan Love Foundation for Breast Cancer Research, is an Associate Editor of Cancer Medicine, and chairs the editorial board of Oncology Times.